Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GARM-Autism
NCT07546942Phase 2Enrolling by invitation
- Start
- Apr 2026
- Primary completion
- Jun 2030
- Modality
- Stem Cell Therapies, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous mesenchymal stromal cells and allogeneic fecal microbiota in Autism Spectrum Disorder (ASD) (2 arms). Primary endpoints: Incidence of adverse events and serious adverse events at 1 year, Socialization Alterations at 1 year and 1 more. Started Apr 2026; status: enrolling by invitation.
02
Drugs
autologous mesenchymal stromal cellsallogeneic fecal microbiota
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT07546942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07546942.